#1. Acid ceramidase (ASAH1) is a key mediator of drug resistance in relapsed/refractory multiple myeloma

MLA

Ryan T. Bishop, et al. “#1. Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Relapsed/Refractory Multiple Myeloma.” Journal of Bone Oncology, vol. 45, no. 100539-, Apr. 2024. EBSCOhost, https://doi.org/10.1016/j.jbo.2024.100539.

APA

Ryan T. Bishop, Tao Li, Raghunandan R. Alugubelli, Mostafa Nasr, Karl J. Nyman, Praneeth Sudalagunta, Mark Meads, Jeremy Frieling, Niveditha Nerlakanti, Marilena Tauro, Oliver Hampton, Bin Fang, Steven Grant, John Koomen, Ariosto Siqueira Silva, Kenneth H. Shain, & Conor C. Lynch. (2024). #1. Acid ceramidase (ASAH1) is a key mediator of drug resistance in relapsed/refractory multiple myeloma. Journal of Bone Oncology, 45(100539-). https://doi.org/10.1016/j.jbo.2024.100539

Chicago

Ryan T. Bishop, Tao Li, Raghunandan R. Alugubelli, Mostafa Nasr, Karl J. Nyman, Praneeth Sudalagunta, Mark Meads, et al. 2024. “#1. Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Relapsed/Refractory Multiple Myeloma.” Journal of Bone Oncology 45 (100539-). doi:10.1016/j.jbo.2024.100539.